A prototype pathogen boundex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model
Open Access
- 1 May 1999
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 29 (5) , 1581-1586
- https://doi.org/10.1002/(sici)1521-4141(199905)29:05<1581::aid-immu1581>3.0.co;2-v
Abstract
Immune complexes (IC) bound to the primate erythrocyte (E) complement receptor (CR1) are cleared from the circulation of primates and localized to the liver. IC can be bound to E CR1 either via C3b opsonization or with cross-linked mAb complexes (heteropolymers, HP) which contain an mAb specific for CR1 and a mAb specific for a prototype pathogen. The long-term goal of our work is to apply the HP to the treatment of human diseases associated with blood-borne pathogens. Therefore we have investigated the feasibility of a non-primate model by studying clearance in mice of bacteriophage ϕX174 bound via HP to primate E. E-HP-ϕX174 complexes were prepared in vitro and infused into the circulation of mice under conditions allowing short term survival of E in the circulation. By radioimmunoassays and flow cytometry, we found that ϕX174 is removed from E and cleared from the circulation coincident with loss of HP and CR1, and that the majority of cleared FX174 is localized to the liver. Through the use of HP constructed with Fab' fragments, we verified the requirement for the Fc portion of the mAb in clearance; inhibition of C3 activation delayed clearance, suggesting a role for complement. The present findings in the mouse confirm previous observations in the non-human primate model.Keywords
This publication has 21 references indexed in Scilit:
- Immune Complexes Bound to the Primate Erythrocyte Complement Receptor (CR1) via Anti-CR1 Mabs Are Cleared Simultaneously with Loss of CR1 in a Concerted Reaction in a Rhesus Monkey ModelClinical Immunology and Immunopathology, 1997
- Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.Proceedings of the National Academy of Sciences, 1996
- Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein‐Barr virus receptor, CR2) that binds iC3b and CD23European Journal of Immunology, 1996
- MICHAEL MASON PRIZE ESSAY 1995: COMPLEMENT, IMMUNE COMPLEXES AND SYSTEMIC LUPUS ERYTHEMATOSUS*Rheumatology, 1996
- Structural requirements regulate endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the cell surface of leukocytes.The Journal of Experimental Medicine, 1995
- Physiological and pathological aspects of circulating immune complexesKidney International, 1989
- Determination of blood volume in the mouse with 51Chromium-labelled erythrocytesJournal of Immunological Methods, 1984
- Primate erythrocyte-immune complex-clearing mechanism.Journal of Clinical Investigation, 1983
- Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.The Journal of Experimental Medicine, 1979
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978